Abstract
Pulmonary arterial hypertension (PAH) is a chronic ailment of the lungs, exhibiting elevated arterial pressure and vascular resistance; with a mean arterial pressure above 25 mmHg at rest and above 30 mmHg during exercise. It is associated with poor prognosis, and its prevalence is estimated to be 15 cases per one million.
The current treatment options for PAH are discussed with the prostanoid class of drugs being the most effective. The latter drugs act by dilating systemic and pulmonary arterial vascular beds and, with sustained long-term usage, altering pulmonary remodelling. They are administered as IV infusions or inhalation solutions. Despite their clinical effectiveness, prostanoids have short half-lives requiring frequent administration of 6-9 times daily and thus suffer from poor compliance.
Controlled release inhalation delivery systems for treatment of PAH, ranging from liposomes, biodegradable nano and microparticles, formation of co-precipitates and complexation with cyclodextrins, are explored. Arising from these formulation strategies, we developed novel polymeric microspheres for inhalation to reduce dosing frequency and improve medication compliance. These microspheres are designed with release modifiers, to reside in the lung which is the site of drug action for a longer duration so as to release the drug slowly and consistently over a prolonged period. This could lead to the development of the first commercially available controlled release inhalation product.
Keywords: Pulmonary arterial hypertension, treatment, inhalation, controlled release, polymeric microspheres.
Current Pharmaceutical Design
Title:Controlled Release Inhalable Polymeric Microspheres for Treatment of Pulmonary Arterial Hypertension
Volume: 21 Issue: 40
Author(s): Aparna Saigal, Wai Kiong Ng, Reginald B.H. Tan and Sui Yung Chan
Affiliation:
Keywords: Pulmonary arterial hypertension, treatment, inhalation, controlled release, polymeric microspheres.
Abstract: Pulmonary arterial hypertension (PAH) is a chronic ailment of the lungs, exhibiting elevated arterial pressure and vascular resistance; with a mean arterial pressure above 25 mmHg at rest and above 30 mmHg during exercise. It is associated with poor prognosis, and its prevalence is estimated to be 15 cases per one million.
The current treatment options for PAH are discussed with the prostanoid class of drugs being the most effective. The latter drugs act by dilating systemic and pulmonary arterial vascular beds and, with sustained long-term usage, altering pulmonary remodelling. They are administered as IV infusions or inhalation solutions. Despite their clinical effectiveness, prostanoids have short half-lives requiring frequent administration of 6-9 times daily and thus suffer from poor compliance.
Controlled release inhalation delivery systems for treatment of PAH, ranging from liposomes, biodegradable nano and microparticles, formation of co-precipitates and complexation with cyclodextrins, are explored. Arising from these formulation strategies, we developed novel polymeric microspheres for inhalation to reduce dosing frequency and improve medication compliance. These microspheres are designed with release modifiers, to reside in the lung which is the site of drug action for a longer duration so as to release the drug slowly and consistently over a prolonged period. This could lead to the development of the first commercially available controlled release inhalation product.
Export Options
About this article
Cite this article as:
Saigal Aparna, Ng Kiong Wai, Tan B.H. Reginald and Chan Yung Sui, Controlled Release Inhalable Polymeric Microspheres for Treatment of Pulmonary Arterial Hypertension, Current Pharmaceutical Design 2015; 21 (40) . https://dx.doi.org/10.2174/1381612821666151008124451
DOI https://dx.doi.org/10.2174/1381612821666151008124451 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Roles of Adrenomedullin in Hypertension and Hypertensive Organ Damage
Current Hypertension Reviews Do We Need More Research on Platelet Function in South Asian Immigrants?
Inflammation & Allergy - Drug Targets (Discontinued) Nephro-Protective Effect of Cortex Lycii Radicis Extracts in Streptozotocin- Induced Diabetic Rats
Current Signal Transduction Therapy Multiple Roles of Fibroblast Growth Factor 21 in Metabolism
Current Pharmaceutical Design Combination of Daidzein, Hemin and Bms182874 Halts the Progression of Diabetes-Induced Experimental Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuroprotective Polyphenols: A Modulatory Action on Neurotransmitter Pathways
Current Neuropharmacology Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis
Current Rheumatology Reviews HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines
Current Molecular Medicine Developments in Non-Surgical Therapies for Abdominal Aortic Aneurysm
Current Vascular Pharmacology Effects of Olive Oil on TNF-α and IL-6 in Humans: Implication in Obesity and Frailty
Endocrine, Metabolic & Immune Disorders - Drug Targets Critical Limb Ischemia: Definition and Natural History
Current Drug Targets - Cardiovascular & Hematological Disorders Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Prostacyclin, Atherothrombosis, and Cardiovascular Disease
Current Medicinal Chemistry Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy
Current Drug Discovery Technologies Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease
Current Protein & Peptide Science Mediterranean Food Pattern in Rheumatoid Arthritis
Current Rheumatology Reviews Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases
Current Pharmaceutical Design Systemic Lupus Erythematosus-Related Interstitial Lung Disease
Current Rheumatology Reviews Uric Acid and Oxidative Stress
Current Pharmaceutical Design Asymmetric Dimethyl-L-Arginine (ADMA): A Possible Link Between Homocyst(e)ine and Endothelial Dysfunction
Current Drug Metabolism